Antibiotics play a major role in acne therapy. Physicians base treatment choices on personal perceptions of efficacy, cost-effectiveness or risk-benefit ratios and rarely take bacterial resistance into account. It is well documented that resistant strains of coagulase-negative staphylococci within the resident skin flora increase in both prevalence and population density as duration of therapy increases. Acne patients represent a considerable reservoir of resistant strains of these important nosocomial pathogens which can be transferred to close contacts. Resistance in cutaneous propionibacteria has received scant attention in view of the central role of Propionibacterium acnes in inflammatory acne. Isolates resistant to one or more anti-acne antibiotics (most commonly erythromycin) have been reported in Europe, the USA, Japan and New Zealand. Carriage of resistant strains results in therapeutic failure of some but not all antibiotic regimens. In our region, skin carriage of resistant strains by 60% of acne patients and 1 in 2 of their close contacts suggests that resistant strains are widely disseminated. We are beginning to gain an understanding of those factors which encourage resistance development and can identify those patients most likely to possess resistant propionibacterial floras. Recommendations for the use of antibiotics in acne therapy to help prevent the emergence of resistance in P. acnes include the implementation of antibiotic usage policies and the encouragement of improved prescribing habits.

Keywords:
Cutaneous propionibacteria, Coagulase-negative staphylococci, Tetracycline, Erythromycin, Clindamycin, Resistance, Acne therapy
1.
Eady EA, Ingham E: Propionibacterium acnes – Friend or foe? Rev Med Microbiol 1994;5: 163–173.
2.
Eady EA, Holland KT, Cunliffe WJ: The use of antibiotics in acne therapy: Oral or topical administration? J Antimicrob Chemother 1982; 10:89–115.
3.
Miller YW, Eady EA, Lacey RW, Cove JH, Joanes DN, Cunliffe WJ: Sequential antibiotic therapy for acne promotes the carriage of resistant staphylococci on the skin of contacts. J Antimicrob Chemother 1996;38:829–837.
4.
Marples RR, Kligman AM: Ecological effects of oral antibiotics on the microflora of human skin. Arch Dermatol 1971;103:148–153.
5.
Leyden JJ, Marples RR, Mills OH, Kligman AM: Tretinoin and antibiotic therapy in acne vulgaris. South Med J 1974;67:20–25.
6.
Eady EA, Cove JH, Holland KT, Cunliffe WJ: Superior antibacterial action and reduced incidence of bacterial resistance in minocycline compared to tetracycline-treated acne patients. Br J Dermatol 1990;122:233–244.
7.
Vowels BR, Feingold DS, Sloughfy C, Foglia AN, Konnikov N, Ordoukhanian E, Starkey P, Leyden JJ: Effects of topical erythromycin on ecology of aerobic cutaneous bacterial flora. Antimicrob Agents Chemother 1996; 40:2598–2604.
8.
Harkaway KS, McGinley KJ, Foglia AN, Lee W-L, Fried F, Shalita AR, Leyden JJ: Antibiotic resistance patterns in coagulase-negative staphylococci after treatment with topical erythromycin, benzoyl peroxide and combination therapy. Br J Dermatol 1992;126:586–590.
9.
Eady EA, Farmery MR, Ross JI, Cove JH, Cunliffe WJ: Effects of benzoyl peroxide and erythromycin alone and in combination against antibiotic-sensitive and -resistant skin bacteria from acne patients. Br J Dermatol 1994;131: 331–336.
10.
Gemmell CG, McCartney AC: Coagulase-negative staphylococci within the hospital environment. Rev Med Microbiol 1990;1: 213–218.
11.
Kloos WE, Bannerman TL: Update on clinical significance of coagulase-negative staphylococci. Clin Microbiol Rev 1994;7:117–140.
12.
Eady EA, Cove JH, Holland KT, Cunliffe WJ: Erythromycin-resistant propionibacteria in antibiotic-treated acne patients: Association with therapeutic failure. Br J Dermatol 1989;121: 51–57.
13.
Bojar RA, Eady EA, Jones CE, Cunliffe WJ, Holland KT: Inhibition of erythromycin-resistant propionibacteria on the skin of acne patients by topical erythromycin with and without zinc. Br J Dermatol 1994;130:329–336.
14.
Eady EA, Bojar RA, Jones CE, Cove JH, Holland KT, Cunliffe WJ: The effects of acne treatment with a combination of benzoyl peroxide and erythromycin on skin carriage of erythromycin-resistant propionibacteria. Br J Dermatol 1996;134:107–113.
15.
Farmery MR, Jones CE, Eady EA, Cove JH, Cunliffe WJ: In vitro activity of azelaic acid, benzoyl peroxide and zinc acetate against antibiotic-resistant propionibacteria from acne patients. J Dermatol Treat 1994;5:63–65.
16.
Guin JD, Lummins WL: Comedonal levels of free clindamycin following topical treatment with a 1% solution of clindamycin phosphate. J Am Acad Dermatol 1982;7:265–268.
17.
Gardner KJ, Cunliffe WJ, Eady EA, Cove JH: Variation in comedonal antibiotic concentrations following application of topical tetracycline for acne vulgaris. Br J Dermatol 1994; 131:649–654.
18.
Layton AM, Hughes BR, Macdonald Hull S, Eady EA, Cunliffe WJ: Seborrhoea – An indicator for poor clinical response in acne patients treated with antibiotics. Clin Exp Dermatol 1992;17:173–175.
19.
Crawford WW, Crawford IP, Stoughton RB, Cornell RC: Laboratory induction and clinical occurrence of combined clindamycin and erythromycin resistance in Corynebacterium acnes. J Invest Dermatol 1979;72:187–190.
20.
Eady EA, Jones CE, Tipper JL, Cove JH, Cunliffe WJ, Layton AM: Antibiotic-resistant propionibacteria in acne: Need for policies to modify antibiotic usage. Br Med J 1993;306: 555–556.
21.
Forssman T: Antibiotikaresistenzen beachten. Therapiewoche 1993;43:2248–2252.
22.
Kurokawa I, Nishijima S, Asada Y: The antibiotic susceptibility of Propionibacterium acnes: A 15-year bacteriological study and retrospective evaluation. J Dermatol 1988;15: 149–154.
23.
Oakley A, Rademaker M, Duffill M, Leng R, Shewan J: Propionibacterium: Resistance of acne to antibiotics. NZ Med J 1995;108:43–44.
24.
Leyden JJ, McGinley KJ, Cavalieri S, Webster GF, Mills OH, Kligman AM: Propionibacterium acnes resistance to antibiotics in acne patients. J Am Acad Dermatol 1983;8:41–45.
25.
Eady EA, Ross JI, Cove JH, Holland KT, Cunliffe WJ: Macrolide-lincosamide-streptogramin B (MLS) resistance in cutaneous propionibacteria: Definition of phenotypes. J Antimicrob Chemother 1989;23:493–502.
26.
Ross JI, Eady EA, Cove JH, Jones CE, Ratyal AH, Miller YW, Vyakrnam S, Cunliffe WJ: Clinical resistance to erythromycin and clindamycin in cutaneous propionibacteria isolated from acne patients is associated with mutations in 23S rRNA. Antimicrob Agents Chemother 1997;41:1162–1165.
27.
Eady EA, Jones CE, Gardner KJ, Taylor JP, Cove JH, Cunliffe WJ: Tetracycline-resistant propionibacteria from acne patients are cross-resistant to doxycycline but sensitive to minocycline. Br J Dermatol 1993;128: 556–560.
28.
Eady EA, Ross JI, Cove JH, Holland KT, Cunliffe WJ: The effects of oral erythromycin therapy for acne on the development of resistance in cutaneous staphylococci and propionibacteria; in Marks R, Plewig G (eds): Acne and Related Disorders. London, Dunitz, 1989, pp 265–270.
1998
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.